ALNY Alnylam Pharmaceuticals Inc.

80.85
+1.71  (+2%)
Previous Close 79.14
Open 79.53
Price To Book 5.12
Market Cap 8,991,138,583
Shares 111,207,651
Volume 537,503
Short Ratio
Av. Daily Volume 706,645
Stock charts supplied by TradingView

NewsSee all news

  1. Alnylam's Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Innovation Chemistry at Alnylam, has been awarded

  2. Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

    – Filing Marks the First RNAi Therapeutic to be Submitted for Potential Approval in Latin America – – Submission Made Under the Accelerated Regulatory Pathway for Rare Diseases – Alnylam Pharmaceuticals, Inc.

  3. Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2019 Cantor Global Healthcare Conference on Thursday, October 3,

  4. Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

    – APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated

  5. Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date under priority review February 4, 2020.
Givosiran
Acute hepatic porphyrias
Phase 3 data met all endpoints - September 25, 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Phase 1/2 additional data due 1H 2020.
ALN-HBV02 (VIR-2218)
Chronic hepatitis B virus (HBV)
Phase 3 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-A
Primary Hyperoxaluria Type 1 (PH1)
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 2 trial to be initiated.
ALN-CC5 (cemdisiran)
IgA nephropathy
Phase 3 ongoing.
Fitusiran (ATLAS)
Hemophilia
Phase 3 trial enrolling - noted December 6, 2018.
ALN-TTRsc02 - HELIOS-A
ATTR amyloidosis
Phase 3 data met all endpoints - September 25, 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 1/2 data due late-2019.
ALN-AAT02
alpha-1 anti-trypsin deficiency-associated liver disease
Phase 3 top-line data due mid-2020.
Lumasiran (ALN-GO1) ILLUMINATE-B
Primary Hyperoxaluria Type 1
Phase 3 trial initiation announced September 16, 2019.
Patisiran APOLLO-B
Wild-type ATTR amyloidosis patients with cardiomyopathy
Phase 3 trial to be initiated 2H 2019.
Lumasiran (ALN-GO1) ILLUMINATE-C
Impaired renal function
Phase 1 dosing has commenced - noted May 31, 2019. Initial data due late-2019.
ALN-AGT
Hypertension
Phase 3 trial to be initiated 2H 2019.
ALN-TTRsc02 (vutrisiran) - HELIOS-B
ATTR amyloidosis with cardiomyopathy

Latest News

  1. Alnylam's Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Innovation Chemistry at Alnylam, has been awarded

  2. Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

    – Filing Marks the First RNAi Therapeutic to be Submitted for Potential Approval in Latin America – – Submission Made Under the Accelerated Regulatory Pathway for Rare Diseases – Alnylam Pharmaceuticals, Inc.

  3. Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2019 Cantor Global Healthcare Conference on Thursday, October 3,

  4. Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

    – APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated

  5. Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on

  6. 1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day

    − Alnylam Supports Nearly 40 Organizations in Greater Boston, Philadelphia, Europe and Brazil in "Helping Hands" Community Service Day – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics

  7. Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias

    − Porphyria Attack Reductions Observed in ENVISION Phase 3 Study Maintained with Ongoing Givosiran Dosing in Open-Label Extension (OLE) Study – − In ENVISION Phase 3 Study, Patients Receiving Givosiran Reported

  8. Alnylam to Host Sixth Annual "RNAi Roundtable" Webcast Series

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it plans to kick off its 6th annual series of "RNAi Roundtable" webcasts over the coming weeks. The series will

  9. Yumanity Therapeutics Appoints Patricia Allen to its Board of Directors

    Ms. Allen Brings Over 25 Years of Financial Leadership Experience to the Company Yumanity Therapeutics, a company focused on discovering and developing transformative therapies to treat neurodegenerative diseases,

  10. Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients

    − Neurofilament Light Chain (NfL) Identified as a Potential Biomarker of Nerve Damage and Polyneuropathy due to hATTR Amyloidosis; ONPATTRO® (patisiran) Treatment Found to Reduce NfL Levels Relative to Placebo in APOLLO

  11. Alnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today provided perspective on the positive complete results from the ORION-11 Phase 3 study of inclisiran, an RNAi therapeutic in

  12. Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17th Annual Morgan Stanley Global Healthcare Conference on